

---

## TABLE OF CONTENTS

1	Introduction.....	1
2	Literature Review.....	8
2.1	Breast cancer.....	8
2.2	Drug and Excipients profile.....	12
2.2.1	Lapatinib.....	12
2.2.2	Solupus® .....	14
2.2.3	Kolliphor™ HS 15.....	15
2.2.4	Kolliphor® 407.....	16
2.3	Nanocarrier drug delivery systems .....	17
2.3.1	Nanocolloidal Micelles as DDS.....	19
2.3.2	Polymeric Micelles: .....	22
2.3.3	Mixed / Binary Micelles.....	25
3	Research Envisage and Plan of Work .....	28
3.1	Aim.....	28
3.2	Objective.....	28
3.3	The rationale of a study: .....	28
3.4	Plan of work.....	29
3.4.1	Preformulation studies.....	29
3.4.2	Formulation development and optimization.....	29

---

3.4.3	Physicochemical characterization.....	29
3.4.4	<i>In-Vitro</i> evaluations .....	30
3.4.5	<i>In-vivo</i> evaluations.....	30
<b>4</b>	<b>Material and Methods.....</b>	<b>31</b>
4.1	Materials, Equipment, Software used .....	31
4.1.1	Materials.....	31
4.1.2	Equipments.....	31
4.1.3	Software .....	32
4.2	Pre-formulation studies .....	32
4.2.1	HPLC analytical method development .....	32
4.2.2	Determination of critical micelle concentration (CMC).....	33
4.2.3	Physicochemical characterization of LP and excipients.....	34
4.3	Formulation Development and optimization.....	34
4.3.1	Screening of components for the formulation of micelles.....	34
4.3.2	Optimization of micelles by Box-Behnken Design .....	35
4.3.3	Formulation of micelles .....	35
4.3.4	Physicochemical characterization.....	37
4.3.5	<i>In-vitro</i> Evaluations .....	39
4.3.6	Stability Studies .....	41
4.3.7	Screening of anticancer efficacy.....	42
4.3.8	<i>In-vivo</i> evaluations.....	43

---

4.4 Statistical Analysis .....	45
<b>5 Results and Discussions.....</b>	<b>46</b>
5.1 Pre-formulation Studies.....	46
5.1.1 HPLC analytical method development .....	46
5.1.2 Determination of critical micelle concentration (CMC) .....	48
5.1.3 Physicochemical characterization of LP and excipients .....	51
5.2 Development, optimization and evaluation of Lapatinib-loaded Polymeric Micelles (LP-PMs).....	53
5.2.1 Screening of components for the formulation of micelles .....	53
5.2.2 Optimization of micelles by Box-Behnken Design (BBD).....	58
5.2.3 Formulation of micelles.....	63
5.2.4 Physicochemical characterization of optimized LP-PMs.....	63
5.2.5 <i>In-vitro</i> Evaluations.....	71
5.2.6 Stability Studies .....	76
5.2.7 <i>In-vitro</i> screening of anticancer efficacy.....	78
5.2.8 <i>In-vivo</i> evaluations .....	82
5.3 Development and evaluation of Lapatinib-loaded Binary Micelles (LP-BMs)...	89
5.3.1 Formulation of LP-BMs .....	89
5.3.2 Physicochemical characterization .....	90
5.3.3 <i>In-vitro</i> Evaluations.....	94
5.3.4 Stability Studies .....	97

---

---

5.3.5	<i>In-vitro</i> screening of anticancer efficacy.....	100
5.3.6	<i>In-vivo</i> evaluations.....	102
<b>6</b>	<b>Summary and Conclusions</b> .....	<b>109</b>
6.1	Summary .....	109
6.2	Conclusions .....	113
	<b>References</b> .....	<b>114</b>
	<b>List of Publications</b> .....	<b>126</b>

---

## LIST OF TABLES

<b>Table 2.1</b>	Characteristics of nanocarrier systems and purpose to use for drug delivery	18
<b>Table 5.1</b>	HPLC validation parameters for the determination of lapatinib.....	47
<b>Table 5.2</b>	Inter and Intraday accuracy and precision for HPLC analytical method validation .....	47
<b>Table 5.3</b>	Quality Target Product Profile.....	53
<b>Table 5.4</b>	Control Impact Matrix.....	54
<b>Table 5.5</b>	Critical process parameters and material attributes .....	54
<b>Table 5.6</b>	Risk Estimation Matrix .....	55
<b>Table 5.7</b>	Details of factors used for Plackett-Burman design.....	56
<b>Table 5.8</b>	Composition of LP-PMs as per BBD design.....	58
<b>Table 5.9</b>	Statistical ANOVA results of quadratic model.....	60
<b>Table 5.10</b>	Predicted and experimental values for optimized LP-PMs .....	60
<b>Table 5.11</b>	Results of evaluations for stability studies .....	76
<b>Table 5.12</b>	Estimated pharmacokinetic parameters of different dosage forms.....	83
<b>Table 5.13</b>	Composition of LP-BMs and the results of evaluations.....	89
<b>Table 5.14</b>	Results of evaluations before and after stability studies. ....	98
<b>Table 5.15</b>	Estimated pharmacokinetic parameters of different dosage forms.....	103

---

## LIST OF FIGURES

Figure 2.1 Histological classification of breast cancer.....	10
Figure 2.2 (a) Molecular classification of breast cancer (b) BC subtypes originating from a single mammary stem cell or progenitor cell after activation by different oncogenes; (c) BC heterogeneity initiate from different mammary stem cells or progenitor cells at distinct levels of stem cells proliferation hierarchy.....	11
Figure 2.3 Chemical structure of drug and excipients .....	14
Figure 2.4 Schematic diagrams depicting different nanocarrier drug delivery systems used for delivery of Lapatinib .....	19
Figure 5.1 Calibration curve of Lapatinib in methanol .....	46
Figure 5.2 Calibration curve of Lapatinib in plasma .....	46
Figure 5.3 Graphs showing CMC determination.....	51
Figure 5.4 Pareto charts showing the influence of process variables .....	57
Figure 5.5 3-D response-surface plots .....	61
Figure 5.6 Morphological characterization of LP-PMs: Histograms (A and B) and zeta potential (C and D) .....	64
Figure 5.7 Morphological characterization of LP-PMs: High resolution-scanning electron microscopic images (A and B) of LP-PMs and lyophilized LP-PMs, respectively; Scanning probe microscopic images (C and E) and their histograms (D and F) of LP-PMs and lyophilized LP-PMs, respectively.....	66
Figure 5.8 (A) FT-IR spectra and (B) XRPD diffractograms of pharmaceutical excipients, LP-PMs (C) EDX spectra of LP-PMs .....	68
Figure 5.9 In-vitro drug release profile of (A) LP-PMs micellar dispersion and (B) lyophilized LP-PMs in release media of pH 5.0 and pH 7.4.....	72

---

Figure 5.10 Hemocompatibility studies .....	75
Figure 5.11 Shelf life plots of LP-PMs .....	77
Figure 5.12 <i>In-vitro</i> anti-cancer efficacy studies of LP-PMs against SKBr3 cell line ..	81
Figure 5.13 Comparative plasma drug concentration profiles .....	82
Figure 5.14 <i>In-vivo</i> anticancer efficacy of LP-PMs .....	85
Figure 5.15 The microscopic images of liver sections after staining with H & E stains .....	86
Figure 5.16 (A) Histogram showing the hydrodynamic diameter and (B) zeta potential of LP-BMs; (C and D) High resolution- scanning electron microscopic image showing spherical shape of LP-BMs and lyophilized LP-BMs, respectively. ....	91
Figure 5.17 (A and B) scanning probe microscopic images showing 2-D and 3-D morphology, respectively; (C) FT-IR spectra of LP-BMs and pharmaceutical excipients .....	92
Figure 5.18 (A) EDX spectra of LP-BMs; (B) In-vitro drug release profile of LP- BMs in release media of pH 5.0 and pH 7.4 .....	94
Figure 5.19 (A) Hemocompatibility of LP-BMs in terms of percent hemolysis; (B) platelet aggregation study .....	96
Figure 5.20 Shelf life plots of LP-BMs.....	99
Figure 5.21 <i>In-vitro</i> anti-cancer efficacy studies of LP-PMs against SKBr3 cell line	101
Figure 5.22 Comparative plasma drug concentration profiles .....	104
Figure 5.23 <i>In-vivo</i> anticancer efficacy of LP-BMs. ....	106
Figure 5.24 The microscopic images of liver sections after staining with H & E stains. ....	107

---